NCT06522737
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06522737
Title A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype (TERZO)
Acronym TERZO
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors SecuraBio
Indications
Therapies
Age Groups: senior | adult
Covered Countries POL | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CZE


No variant requirements are available.